Rinvoq (upadacitinib) is a once-daily oral medication approved to treat several inflammatory conditions, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, ankylosing spondylitis, psoriatic arthritis, non-radiographic axial spondyloarthritis, giant cell arteritis, and polyarticular juvenile idiopathic arthritis. It works by dialing down an overactive immune system, and it’s typically prescribed after other treatments haven’t provided enough relief.
How Rinvoq Works
Rinvoq belongs to a class of drugs called JAK inhibitors. Your immune system relies on a signaling chain: when an immune messenger (called a cytokine) docks onto a cell, it triggers enzymes known as Janus kinases (JAKs) inside the cell. Those enzymes pass the signal to the cell’s nucleus, where the inflammatory response ramps up. Rinvoq blocks this relay, primarily targeting JAK1, which helps reduce the inflammation driving conditions like arthritis, eczema, and inflammatory bowel disease.
Unlike injectable biologics that target a single cytokine outside the cell, Rinvoq works inside the cell and influences multiple inflammatory pathways at once. This broader reach can be an advantage for people who haven’t responded to more targeted therapies, though it also means the drug affects parts of the immune system beyond just the disease being treated.
Rheumatoid Arthritis
Rheumatoid arthritis was the first condition Rinvoq was approved to treat, receiving FDA clearance in 2019. It’s used for adults with moderate to severe RA who didn’t respond well enough to methotrexate or similar medications. The standard dose is 15 mg once daily.
Clinical trial results were strong. Across multiple large studies, roughly 64% to 76% of patients on Rinvoq 15 mg achieved at least a 20% improvement in joint symptoms at 12 weeks, compared to 28% to 54% on placebo or methotrexate alone. About 34% to 52% hit the higher bar of 50% improvement. In one head-to-head trial, Rinvoq outperformed adalimumab (a widely used biologic): 71% of Rinvoq patients reached the 20% improvement mark versus 63% on adalimumab, with an even wider gap at the 50% threshold (45% vs. 29%).
Atopic Dermatitis
Rinvoq is approved for adults and children 12 and older (weighing at least 88 pounds) with moderate to severe atopic dermatitis that hasn’t been adequately controlled by other treatments. The typical starting dose is 15 mg daily, though some adults may be prescribed 30 mg. For many people with eczema that hasn’t responded to topical steroids or other systemic therapies, Rinvoq can significantly reduce itch and clear skin within the first few weeks of treatment.
Ulcerative Colitis
For adults with moderate to severe ulcerative colitis, Rinvoq uses a two-phase dosing approach. Treatment starts with a higher induction dose of 45 mg daily for 8 weeks to get symptoms under control, then drops to 15 mg daily for ongoing maintenance. In clinical trials, 26% to 34% of patients achieved clinical remission during the induction phase, compared with just 4% to 5% on placebo. After a full year of maintenance therapy, 42% of patients on the 15 mg dose remained in remission versus 12% on placebo.
Crohn’s Disease
Rinvoq follows a similar pattern for Crohn’s disease: a 45 mg daily induction dose for 12 weeks (slightly longer than the ulcerative colitis timeline), followed by 15 mg daily for maintenance. This condition often requires a longer ramp-up because inflammation in Crohn’s can affect deeper layers of the intestinal wall and may take more time to respond.
Ankylosing Spondylitis and Axial Spondyloarthritis
Rinvoq is approved for two forms of spinal inflammatory arthritis: ankylosing spondylitis (where structural damage is visible on X-rays) and non-radiographic axial spondyloarthritis (where inflammation exists but hasn’t yet caused visible joint damage). Both are treated with 15 mg daily.
In the SELECT-AXIS 2 trial for non-radiographic axial spondyloarthritis, 44.9% of patients on Rinvoq achieved at least a 40% improvement in disease activity at 14 weeks, compared to 22.3% on placebo. Improvements showed up as early as week two and extended beyond pain relief to include better physical function, quality of life, and reduced inflammation on MRI of the sacroiliac joints.
Other Approved Conditions
Rinvoq also carries approvals for several additional conditions:
- Psoriatic arthritis: For adults and children 2 and older (weighing at least 66 pounds) with active psoriatic arthritis, at a dose of 15 mg daily.
- Giant cell arteritis: For adults, at 15 mg daily. It’s initially used alongside a tapering course of steroids, then continued alone after steroids are stopped.
- Polyarticular juvenile idiopathic arthritis: For children 2 and older, with dosing based on body weight. A liquid formulation is available for younger or smaller children who can’t swallow tablets.
Positioning in Treatment
For most of its approved conditions, Rinvoq is not a first-line therapy. It’s generally reserved for people who tried and failed other treatments, whether that’s methotrexate for arthritis, topical therapies for eczema, or biologics for inflammatory bowel disease. This positioning reflects both the drug’s potency and its safety profile, which carries more serious risks than many first-line options.
Common Side Effects
The most frequently reported side effects include upper respiratory infections (like colds and sinus infections), nausea, cough, and fever. Acne is notably common, particularly in younger patients and those being treated for atopic dermatitis. Elevated liver enzymes and changes in cholesterol levels can also occur, which is why routine blood work is part of ongoing monitoring.
Shingles (herpes zoster reactivation) occurs more often in people taking Rinvoq than in the general population. Vaccination against shingles is generally recommended before starting treatment when possible.
Serious Risks
Rinvoq carries the FDA’s most prominent safety alert, a boxed warning, covering five categories of serious risk. These warnings apply to all JAK inhibitors, not just Rinvoq, and are based largely on a large safety study of a different JAK inhibitor in older rheumatoid arthritis patients with cardiovascular risk factors.
- Serious infections: Because Rinvoq suppresses immune function, it increases vulnerability to infections including tuberculosis, fungal infections, and viral reactivation. Screening for tuberculosis and hepatitis B and C is required before starting treatment.
- Malignancies: Lymphoma and other cancers have been observed in patients on JAK inhibitors at higher rates than those on older biologic therapies. Current and former smokers face additional risk.
- Cardiovascular events: Heart attacks and strokes occurred at higher rates in older RA patients with pre-existing cardiovascular risk factors taking a JAK inhibitor compared to those on biologic alternatives. Smoking again compounds the risk.
- Blood clots: Deep vein thrombosis, pulmonary embolism, and arterial clots have been reported, some fatal.
- Mortality: A higher rate of all-cause death was observed with another JAK inhibitor compared to biologic alternatives in the same high-risk RA population.
Before Starting Rinvoq
Several screening steps happen before you begin treatment. You’ll be tested for tuberculosis and viral hepatitis, and blood work will check your white blood cell counts and hemoglobin levels. Women of reproductive age need a pregnancy test, since Rinvoq can cause harm to a developing fetus based on animal studies. You should not take Rinvoq alongside other JAK inhibitors, biologic medications, or strong immunosuppressants like azathioprine or cyclosporine. Live vaccines (such as the live shingles vaccine or MMR) should be avoided while on the drug.
People with severe liver impairment or active serious infections are not candidates for Rinvoq. If your lymphocyte or neutrophil counts fall below certain thresholds, or your hemoglobin drops too low, treatment will be paused until levels recover.